On the public citation graph

Synthesis and Study of Hynic Conjugated Psma Targeting Ligands for Prostate Cancer Diagnosis

0 signed · 54 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cmdc.202000085openalex-extracted
[18F]Flurpiridaz: Facile and Improved Precursor Synthesis for this Next‐Generation Cardiac Positron Emission Tomography Imaging Agent
inferredcites →https://doi.org/10.1002/jmrs.227openalex-extracted
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
inferredcites →https://doi.org/10.1002/pros.23444openalex-extracted
99mTc‐MIP‐1404‐SPECT/CT for the detection of PSMA‐positive lesions in 225 patients with biochemical recurrence of prostate cancer
inferredcites →https://doi.org/10.1007/b101226openalex-extracted
6-Hydrazinonicotinamide Derivatives as Bifunctional Coupling Agents for 99mTc-Labeling of Small Biomolecules
inferredcites →https://doi.org/10.1007/s00259-010-1488-zopenalex-extracted
A fast cardiac gamma camera with dynamic SPECT capabilities: design, system validation and future potential
inferredcites →https://doi.org/10.1007/s00259-012-2298-2openalex-extracted
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
inferredcites →https://doi.org/10.1007/s00259-013-2606-5openalex-extracted
The origins of SPECT and SPECT/CT
inferredcites →https://doi.org/10.1007/s00259-019-04404-6openalex-extracted
Two decades of SPECT/CT – the coming of age of a technology: An updated review of literature evidence
inferredcites →https://doi.org/10.1007/s10967-021-08173-1openalex-extracted
Preclinical evaluation of 188Re-HYNIC-PSMA as a novel therapeutic agent
inferredcites →https://doi.org/10.1007/s11307-015-0850-8openalex-extracted
Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
inferredcites →https://doi.org/10.1007/s11307-023-01881-yopenalex-extracted
The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer
inferredcites →https://doi.org/10.1016/0734-9750(93)90273-popenalex-extracted
5162504 Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
inferredcites →https://doi.org/10.1016/j.bioorg.2020.103743openalex-extracted
Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen
inferredcites →https://doi.org/10.1016/j.bmcl.2012.09.014openalex-extracted
Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates
inferredcites →https://doi.org/10.1016/j.ejmcr.2021.100014openalex-extracted
Total chemical synthesis of PSMA-11: API for 68Ga-PSMA-11 used for prostate cancer diagnosis
inferredcites →https://doi.org/10.1016/j.ejmcr.2022.100084openalex-extracted
A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications
inferredcites →https://doi.org/10.1016/j.ica.2010.01.009openalex-extracted
Hydrazinonicotinic acid (HYNIC) – Coordination chemistry and applications in radiopharmaceutical chemistry
inferredcites →https://doi.org/10.1016/j.ica.2012.03.002openalex-extracted
Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: Effects of chelate design on pharmacokinetics
inferredcites →https://doi.org/10.1016/j.nucmedbio.2017.01.010openalex-extracted
99m Tc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen
inferredcites →https://doi.org/10.1016/j.nucmedbio.2017.01.012openalex-extracted
Clinical translation of a PSMA inhibitor for 99m Tc-based SPECT
inferredcites →https://doi.org/10.1016/s0040-4039(97)01690-0openalex-extracted
Use of Alloc-amino acids in solid-phase peptide synthesis. Tandem deprotection-coupling reactions using neutral conditions
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b01210openalex-extracted
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors
inferredcites →https://doi.org/10.1021/bc200279bopenalex-extracted
68 Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
inferredcites →https://doi.org/10.1021/jm100623eopenalex-extracted
68 Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer
inferredcites →https://doi.org/10.1021/jm400823wopenalex-extracted
Effect of Chelators on the Pharmacokinetics of 99mTc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA)
inferredcites →https://doi.org/10.1021/jm800111uopenalex-extracted
Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)
inferredcites →https://doi.org/10.1021/mp9000712openalex-extracted
Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
inferredcites →https://doi.org/10.1038/s41598-020-61129-5openalex-extracted
Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer
inferredcites →https://doi.org/10.1039/b705111eopenalex-extracted
How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies
inferredcites →https://doi.org/10.1053/j.semnuclmed.2022.01.004openalex-extracted
Recent Developments in SPECT/CT
inferredcites →https://doi.org/10.1056/nejmoa2107322openalex-extracted
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1063/1.5091805openalex-extracted
Room temperature semiconductor detectors for nuclear security
inferredcites →https://doi.org/10.1073/pnas.93.2.749openalex-extracted
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.
inferredcites →https://doi.org/10.1097/00004728-198406000-00028openalex-extracted
Analysis of Emission Tomographic Scan Data: Limitations Imposed by Resolution and Background
inferredcites →https://doi.org/10.1155/2011/796025openalex-extracted
Molecular SPECT Imaging: An Overview
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-2690openalex-extracted
Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen:In vivoImaging in Experimental Models of Prostate Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-1357openalex-extracted
2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-22-2875openalex-extracted
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1162/15353500200202109openalex-extracted
11 C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)
inferredcites →https://doi.org/10.1186/s40001-023-01627-0openalex-extracted
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
inferredcites →https://doi.org/10.1186/s41181-024-00279-7openalex-extracted
Recently developed radiopharmaceuticals for bacterial infection imaging
inferredcites →https://doi.org/10.1515/ract-2023-0205openalex-extracted
Total chemical synthesis of PSMA-617: an API for prostate cancer endotherapeutic applications
inferredcites →https://doi.org/10.1515/ract-2024-0280openalex-extracted
Challenges in the solution phase synthesis of PSMA-11 and PSMA-617: organic ligands for radiopharmaceutical preparations in prostate cancer medication
inferredcites →https://doi.org/10.2310/7290.2005.05163openalex-extracted
High-affinity Near-infrared Fluorescent Small-molecule Contrast Agents for In Vivo Imaging of Prostate-specific Membrane Antigen
inferredcites →https://doi.org/10.23736/s1824-4785.20.03230-6openalex-extracted
Current and novel radiopharmaceuticals for imaging cardiovascular inflammation
inferredcites →https://doi.org/10.2967/jnumed.112.116624openalex-extracted
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer
inferredcites →https://doi.org/10.2967/jnumed.116.186767openalex-extracted
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
inferredcites →https://doi.org/10.2967/jnumed.117.191031openalex-extracted
PSMA Ligands for PET Imaging of Prostate Cancer
inferredcites →https://doi.org/10.2967/jnumed.118.212233openalex-extracted
Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
inferredcites →https://doi.org/10.3390/cancers13246183openalex-extracted
New Radionuclides and Technological Advances in SPECT and PET Scanners
inferredcites →https://doi.org/10.3390/cancers2021125openalex-extracted
Markers for Detection of Prostate Cancer
inferredcites →https://doi.org/10.3390/molecules27092617openalex-extracted
A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer
inferredcites →https://doi.org/10.3390/ph7070779openalex-extracted
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
inferredcites →https://doi.org/10.1162/153535002320162750openalex-snapshot
11C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase)
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.